Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Reuters
16 May
Rein <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Rein Therapeutics Inc., a biopharmaceutical company focusing on orphan pulmonary and fibrosis indications, reported a net loss of $5.5 million for the first quarter ended March 31, 2025, a decrease from the $7.1 million net loss experienced in the same period in 2024. This translated to a basic and diluted net loss per share of $0.25, compared to $0.86 in the prior year. The company's cash and cash equivalents stood at $7.4 million as of March 31, 2025, down from $12.9 million at the end of 2024. However, Rein has extended its cash runway through September 2025 following warrant transactions and a private placement that raised approximately $5.28 million in April 2025. Research and Development expenses decreased to $3.1 million from $3.5 million in the previous year, largely due to a temporary delay in further clinical development of LTI-01. General and Administrative expenses also saw a reduction to $2.5 million from $3.7 million, attributed primarily to decreased professional fees and employee-related costs. Rein Therapeutics has also initiated the RENEW Phase 2 trial for LTI-03 in idiopathic pulmonary fibrosis, with interim data expected in the first half of 2026, and has had two abstracts accepted to the American Thoracic Society 2025 International Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA89456) on May 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10